Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA.
BioDrugs. 2021 Jan;35(1):19-33. doi: 10.1007/s40259-020-00454-7.
Acute graft-versus-host disease (GVHD), the major complication after allogeneic hematopoietic cell transplant (HCT), develops in approximately 50% of patients. The primary treatment is high-dose systemic steroids, but treatment failure is common, and steroid-refractory (SR) GVHD is the leading cause of non-relapse mortality after allogeneic HCT. Ruxolitinib became the first treatment for SR GVHD to obtain US Food and Drug Administration approval, and other new treatments are actively being studied. We searched the literature using the PubMed database and clinical trials using ClinicalTrials.gov to identify the most promising new treatments for GVHD. In this review, we categorize potential new treatments for GVHD by their mechanism of action (e.g., antibodies that deplete T cells or prevent their trafficking to target tissues, proteasome inhibitors, tyrosine kinase inhibitors, and other agents) and summarize the results from clinical trials.
急性移植物抗宿主病（GVHD）是异基因造血细胞移植（HCT）后主要并发症之一，约 50%的患者会发生。其主要治疗方法是大剂量全身性皮质类固醇，但治疗失败较为常见，而类固醇难治性（SR）GVHD 是异基因 HCT 后非复发死亡率的主要原因。芦可替尼成为首个获得美国食品和药物管理局批准用于治疗 SR GVHD 的药物，其他新的治疗方法也正在积极研究中。我们使用 PubMed 数据库搜索文献，并在 ClinicalTrials.gov 上搜索临床试验，以确定最有前途的 GVHD 新治疗方法。在这篇综述中，我们根据作用机制（例如，清除 T 细胞或阻止其向靶组织转移的抗体、蛋白酶体抑制剂、酪氨酸激酶抑制剂和其他药物）对潜在的 GVHD 新治疗方法进行分类，并总结临床试验结果。
